Body adhesive sheets

Abstract

To provide a body adhesive sheet that can give the user a sufficient cooling sensation, a comfortable feel with minimal irritation, and a noticeable effect of clearing the head. [Solution] The body adhesive sheet of the present invention has a gel layer. The gel layer contains (A) carbon dioxide, (B) TRPM8 agonist, and (C) water. The content of component (A) in the gel layer is 5 g / m². 2 The above is true. The content of component (B) in the gel layer is 0.001% by mass or more and 0.20% by mass or less. The thickness of the gel layer is 1.5 mm or more. It is preferable that component (B) contains (B1) menthoxypropanediol or menthyl lactate and (B2) menthol.

Description

[Technical Field]

[0001] This invention relates to a sheet for application to the body. [Background technology]

[0002] Articles that provide a cooling sensation when applied to the human body are known. For example, Patent Document 1 proposes a sheet-like coolant that can cool the body by utilizing the latent heat of water when applied to the human body. Furthermore, the applicant previously proposed a sheet-like cosmetic composition having a gel layer and containing carbon dioxide and menthol, etc. (see Patent Documents 2 and 3). [Prior art documents] [Patent Documents]

[0003] [Patent Document 1] Japanese Patent Publication No. 2002-241747 [Patent Document 2] Japanese Patent Publication No. 2018-177775 [Patent Document 3] Japanese Patent Publication No. 2018-177776 [Overview of the project] [Problems that the invention aims to solve]

[0004] According to the sheet-like agent described in Patent Document 1, although the temperature of the skin surface directly beneath the application site decreases, the effect of improving blood flow at the application site and the feeling of refreshment in the head are insufficient. The sheet-type cosmetic formulations described in Patent Documents 2 and 3 provide a sufficiently high blood flow promoting effect even when applied to areas with thin skin, a high density of temperature receptors, and heightened sensitivity to hot and cold stimuli. However, depending on the application site, strong irritation may be felt, which may result in an unpleasant and comfortable user experience. Furthermore, if the amount of menthol, a substance that promotes blood circulation, is reduced in order to reduce strong irritation, the feeling of mental clarity may not be as pronounced. Therefore, an object of the present invention is to provide a body-attaching sheet that is less likely to feel strong stimuli, has a comfortable feeling of use, and can give a feeling of the effect of clearing the head.

Means for Solving the Problems

[0005] The present invention provides a body-attaching sheet having a gel layer. In one embodiment of the present invention, the gel layer contains the following components (A), (B) and (C): (A) Carbon dioxide (B) TRPM8 agonist (C) Water It is preferably contained. In one embodiment of the present invention, the content of the component (A) in the gel layer is preferably 5 g / m 2 or more. In one embodiment of the present invention, the content of the component (B) in the gel layer is preferably 0.001% by mass or more and 0.20% by mass or less. In one embodiment of the present invention, the thickness of the gel layer is preferably 1.5 mm or more.

Effects of the Invention

[0006] According to the body-attaching sheet of the present invention, it has sufficient coolness and persistence of coolness, and can give the user a comfortable feeling of use with few strong stimuli and a feeling of the effect of clearing the head.

Mode for Carrying Out the Invention

[0007] Hereinafter, the present invention will be described based on its preferred embodiments. The body-attaching sheet of the present invention is typically used by directly attaching it to the human skin. By attaching the body-attaching sheet of the present invention to the human skin, as described below, it is possible to perceive sufficient coolness and a comfortable feeling of use without giving strong stimuli, the coolness persists, and moreover, it is possible to perceive a feeling of the effect of clearing the head. The inventors, in order to give users a sufficient cooling sensation, incorporated a large amount of cooling agent, but they found that this resulted in excessive sensory stimulation depending on the area where the sheet was applied. For example, with conventional sheets of this type, it was customary to apply the sheet to the forehead to give users the feeling of a clear head, but it was found that this could cause excessive sensory stimulation to the user. On the other hand, the idea of ​​applying the sheet to a part of the body other than the forehead to give users the feeling of a clear head had not existed before.

[0008] The body-adhesive sheet of the present invention has a gel layer. In this invention, the adhesive properties of the gel layer are utilized to directly adhere the body-adhesive sheet to human skin. When the body-adhesive sheet is applied, the gel layer is in direct contact with the human skin, making it possible to absorb the components contained in the gel layer transdermally into the human body. Therefore, in this invention, the gel layer contains the main components of the sheet of the present invention. More specifically, it is preferable that the gel layer contains the following components (A), (B), and (C). (A) Carbon dioxide (B) TRPM8 Agonist (C)Water The following explains each of these ingredients.

[0009] The gel layer of the body adhesive sheet of the present invention contains carbon dioxide, which is component (A). When the body adhesive sheet of the present invention is applied to the skin, the blood circulation promoting effect is enhanced and sustained by the carbon dioxide. Sheets having a gel layer containing carbon dioxide are conventionally known, but one of the features of the body adhesive sheet of the present invention is that the amount of carbon dioxide contained in the gel layer is greater than that of conventional sheets. Specifically, the body adhesive sheet of the present invention has a carbon dioxide content of 5 g / m² in the gel layer. 2It is preferable that it is as above. By containing such a large amount of carbon dioxide gas in the gel layer, a high concentration of carbon dioxide gas can be supplied to the user over a long period of time. As a result, it brings the advantage that the blood circulation promoting effect is enhanced and the blood flow rate increases. These advantages are extremely advantageous from the viewpoint of making the user perceive the effect of feeling refreshed. Moreover, surprisingly, by attaching the body-attaching sheet of the present invention to a body part other than the forehead, the user can also perceive the effect of feeling refreshed. From the viewpoint of further enhancing these advantages, the content of carbon dioxide gas in the gel layer is 5.5 g / m 2 It is more preferable that it is above, and 6 g / m 2 It is even more preferable that it is above. The higher the content of carbon dioxide gas in the gel layer, the more desirable it is from the viewpoint of enhancing the blood circulation promoting effect. On the other hand, from the viewpoint of manufacturing considering the solubility of carbon dioxide gas, the content of carbon dioxide gas in the gel layer is preferably 80 g / m 2 or less, more preferably 60 g / m 2 or less, even more preferably 40 g / m 2 or less, still more preferably 20 g / m 2 or less, and even more preferably 20 g / m or less. Taking the above points into consideration, the content of carbon dioxide gas in the gel layer is preferably 5 g / m 2 or more and 80 g / m 2 or less, more preferably 5.5 g / m 2 or more and 60 g / m 2 or less, even more preferably 6 g / m 2 or more and 40 g / m 2 or less, still more preferably 6 g / m 2 or more and 20 g / m 2 or less, and even more preferably 20 g / m or less. A method for containing carbon dioxide gas in the gel layer will be described later.

[0010] The amount of carbon dioxide gas contained in the gel layer is measured, for example, by the following method. When the viscosity of the gel layer is low (1000 Pa·s or less), the amount of carbon dioxide can be measured using a carbon dioxide electrode at room temperature (25°C) without diluting the gel layer. On the other hand, if the viscosity of the gel layer is high (over 1000 Pa·s), the gel layer is placed in a lidded container with an alkaline solution and thoroughly immersed to trap carbon dioxide as carbonate in the aqueous solution. Then, the pH of the aqueous solution is made acidic with an acidic buffer solution. The carbon dioxide concentration of the aqueous solution at room temperature (25°C) is measured using a carbon dioxide electrode. The carbon dioxide concentration in the gel layer is calculated based on the obtained carbon dioxide concentration, the mass of the gel layer, and the volume of the aqueous solution. Furthermore, the concentration per unit area (m²) is calculated based on the thickness of the gel layer. 2 The volume of the gel layer per unit area (g / m²) is calculated, and by multiplying this by the carbon dioxide concentration in the gel layer, the amount of carbon dioxide per unit area of ​​the sheet (g / m²) is calculated. 2 Calculate ).

[0011] As described above, one of the features of the body adhesive sheet of the present invention is that the gel layer contains a large amount of carbon dioxide. From the viewpoint of enhancing the blood circulation promoting effect and allowing the user to perceive a feeling of mental clarity, the concentration of carbon dioxide in the gel layer is preferably 750 ppm or more, more preferably 1000 ppm or more, and even more preferably 1250 ppm or more. While a higher concentration of carbon dioxide in the gel layer is preferable because it makes it easier for users to perceive a feeling of mental clarity, practically speaking, the intended purpose can be sufficiently achieved if the carbon dioxide concentration in the gel layer is around 2500 ppm. In this specification, "ppm" refers to a value based on mass.

[0012] To ensure the gel layer contains a sufficient amount of carbon dioxide, it is advantageous to set a high basis weight for the gel layer. From this perspective, the basis weight of the gel layer should be 1500 g / m². 2 Preferably, it should be 1700g / m² or more. 2 It is even more preferable that the amount be greater than or equal to 1900 g / m². 2 It is even more preferable that the above conditions are met. The higher the basis weight of the gel layer, the more advantageous it is for carbon dioxide content, but a basis weight of 3200 g / m² is preferable. 2 If the carbon dioxide level is high enough, it becomes possible to incorporate an amount of carbon dioxide into the gel layer sufficient to fully achieve the effects of the present invention. The basis weight of the gel layer can be adjusted by the amount of water (component C), as well as the type and amount of gelling agent.

[0013] In relation to the basis weight of the gel layer, increasing the thickness of the gel layer is advantageous from the viewpoint of containing a sufficient amount of carbon dioxide in the gel layer. From this viewpoint, the thickness of the gel layer is preferably 1.5 mm or more, more preferably 2 mm or more, and even more preferably 3 mm or more. The greater the thickness of the gel layer, the more advantageous it is for carbon dioxide content. However, if the thickness becomes excessively large, the adhesiveness and feel of the body-adhesive sheet of the present invention may decrease. From this viewpoint, the thickness of the gel layer is preferably 10 mm or less, more preferably 8 mm or less, and even more preferably 6 mm or less. The thickness of the gel layer is measured under no load using a laser displacement meter.

[0014] The component (B) contained in the gel layer, the TRPM8 agonist, is an agonist that acts on TRPM8, a cold receptor among the temperature-sensitive TRP channels present in the body. There are no restrictions on the type of TRPM8 agonist, as long as it is a compound that activates the TRPM8 channel. Examples of TRPM8 agonists include menthol such as L-menthol and DL-menthol, menthanediol, cineole, menthyl glyceryl ether, menthyl lactate, menthyl succinate, menthyl glutarate, menthylpyrrolidone carboxylic acid, ethyl menthanecarboxamide, menthanecarbonylglycine ethyl ester, menthyl ethylaminooxalic acid, menthol glycerin acetal, butylcyclohexanone, isopulegol, trimethylisopropylbutanamide, menthoxypropanediol, camphor, ishirin, N-(ethoxycarbonylmethyl)-3-p-menthanecarboxamide, and N-ethyl-p-menthane-3-carboxamide. Alternatively, you may use plant or essential oils containing TRPM8 agonists, such as peppermint oil, spearmint oil, or eucalyptus oil. These TRPM8 agonists may be used individually or in combination of two or more types.

[0015] TRPM8 agonists, through interaction with carbon dioxide as described above, enhance the duration of the blood circulation-promoting effect and provide a cooling sensation to the user. As a result of diligent research, the inventors have found that when the carbon dioxide content in the gel layer is above a predetermined amount, even a relatively small amount of TRPM8 agonist in the gel layer can provide a sufficient blood circulation-promoting effect and produce a refreshing head effect. Furthermore, by using a small amount of TRPM8 agonist, when the body adhesive sheet of the present invention is applied to an area sensitive to cold and pain, such as the forehead, it is possible to provide the user with a pleasant cooling sensation without causing strong irritation, and also to perceive a refreshing head effect. From the viewpoint of reliably exhibiting these advantages, the TRPM8 agonist content in the gel layer is preferably 0.001% by mass or more, more preferably 0.01% by mass or more, and even more preferably 0.05% by mass or more. Furthermore, from the viewpoint of preventing excessive irritation to the user caused by the TRPM8 agonist, the TRPM8 agonist content in the gel layer is preferably 0.20% by mass or less, and more preferably 0.15% by mass or less.

[0016] The amount of TRPM8 agonist in the gel layer is determined based on the extent to which the user perceives the cooling sensation, comfortable feel, and refreshing effect caused by the interaction between the large amount of carbon dioxide contained in the gel layer and the TRPM8 agonist. The inventors' research has shown that using a combination of two or more substances as TRPM8 agonists is advantageous in order to provide users with a balanced perception of these sensations. In particular, using a combination of two substances as TRPM8 agonists allows for a comfortable user experience without strong irritation, even when the body adhesive sheet of the present invention is applied to the forehead, a part of the body that is highly sensitive to cold and pain, due to the further interaction between the large amount of carbon dioxide contained in the gel layer and the TRPM8 agonists. Furthermore, even when applied to the forehead or other parts of the body, the user can effectively perceive a refreshing effect.

[0017] In particular, using a combination of two TRPM8 agonists with different TRPA1 activity levels is advantageous because it effectively provides users with a sufficient cooling sensation, a comfortable feel with minimal irritation, and a noticeable head-clearing effect. This advantage becomes even more pronounced when combining a TRPM8 agonist with high TRPA1 activity with one with low TRPA1 activity.

[0018] From the above perspective, TRPM8 agonists contain the following components (B1) and (B2): (B1) Menthoxypropanediol or Menthyl Lactate (B2) Menthol It is preferable that the TRPM8 agonist contains the following, and it is even more preferable that the TRPM8 agonist consists of component (B1) and component (B2). Component (B1) is a TRPM8 agonist with low TRPA1 activity. Component (B2) is a TRPM8 agonist with high TRPA1 activity. TRPA1 is a type of ion channel and is a receptor primarily involved in pain perception, temperature sensation, and responses to chemical stimuli.

[0019] When the TRPM8 agonist contains the above-mentioned components (B1) and (B2), from the viewpoint of providing users with a good balance of sufficient cooling sensation, a comfortable feel with minimal irritation, and a noticeable effect of clearing the head, the mass ratio of component (B2) to component (B1) is preferably 0.05 or higher, more preferably 0.1 or higher, even more preferably 0.25 or higher, and even more preferably 0.8 or higher. From a similar viewpoint, the mass ratio of component (B2) to component (B1) is preferably 10 or less, more preferably 9 or less, even more preferably 8 or less, even more preferably 4 or less, and particularly preferably 3 or less. Considering the above points, the mass ratio of component (B2) to component (B1) is preferably 0.05 or more and 10 or less, more preferably 0.1 or more and 9 or less, even more preferably 0.25 or more and 8 or less, even more preferably 0.8 or more and 4 or less, and particularly preferably 0.8 or more and 3 or less.

[0020] In relation to the mass ratio of component (B2) / component (B1), from the viewpoint of providing users with a well-balanced perception of sufficient cooling sensation, a comfortable feel with less strong irritation, and a more refreshing effect on the head, the content of component (B1) in the gel layer is preferably 0.001% by mass or more, more preferably 0.0015% by mass or more, and even more preferably 0.002% by mass or more, provided that the content of TRPM8 agonist in the gel layer is within the range described above. From a similar viewpoint, the content of component (B1) in the gel layer is preferably 0.191% by mass or less, more preferably 0.165% by mass or less, and even more preferably 0.143% by mass or less.

[0021] On the other hand, the content of component (B2) in the gel layer is preferably 0.0005% by mass or more, more preferably 0.005% by mass or more, and even more preferably 0.0075% by mass or more, provided that the content of TRPM8 agonist in the gel layer is within the range described above, from the viewpoint of providing users with a good balance of sufficient cooling sensation, a comfortable feel with less strong irritation, and a more refreshing effect on the head. Similarly, the content of component (B2) in the gel layer is preferably 0.182% by mass or less, more preferably 0.159% by mass or less, and even more preferably 0.136% by mass or less.

[0022] The gel layer is in a hydrogel state because it contains water, which is component (C). From the viewpoint of containing a high concentration of carbon dioxide in the gel layer, the water content in the gel layer is preferably 60% by mass or more, more preferably 65% ​​by mass or more, and even more preferably 70% by mass or more. Furthermore, from the viewpoint of maintaining the gel state of the gel layer, the water content in the gel layer is preferably 90% by mass or less, more preferably 87% by mass or less, and even more preferably 85% by mass or less. Details of the gelling agent used to create a hydrated gel layer will be described later.

[0023] In the body adhesive sheet of the present invention, the gel layer further comprises the following component (D): (D) Ester oil It is preferable that it contains [a certain substance]. The gel layer containing ester oil can further enhance the blood circulation promoting effect. Examples of ester oils include monoglycerides of saturated or unsaturated fatty acids, diglycerides of saturated or unsaturated fatty acids, and triglycerides of saturated or unsaturated fatty acids. The number of carbon atoms in the fatty acid residues in the glycerides is preferably 2 to 18, and more preferably 6 to 18. Specific examples of ester oils include monoester oils such as isopropyl myristate, isononyl isononanoate, and isotridecyl isononanoate; diester oils such as neopentyl glycol dicaprate; and triester oils consisting of triglycerides of saturated or unsaturated fatty acids with 6 to 18 carbon atoms, such as tri(caprylic / capric acid)glyceryl, tri(2-ethylhexanoate)glyceryl, and tri(oleic acid)glyceryl. These ester oils may be used individually or in combination of two or more. Among the various ester oils mentioned above, it is preferable to use tri(caprylic / capric acid) glyceryl, isopropyl myristate, or isononyl isononanoate because of their good compatibility with components (A) and (B).

[0024] When ester oil is incorporated into the gel layer, the ester oil content is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and even more preferably 0.1% by mass or more, from the viewpoint of mitigating the irritation of the TRPM8 agonist, enhancing the duration of the cooling sensation, and providing a feeling of a refreshing effect on the head. Furthermore, the ester oil content in the gel layer is preferably 3% by mass or less, more preferably 2.8% by mass or less, and even more preferably 2.5% by mass or less, from the viewpoint of not suppressing the cooling sensation of the TRPM8 agonist too much, not interfering with the blood circulation promoting effects of carbon dioxide and menthol, and providing an effective feeling of a refreshing effect on the head.

[0025] Adjusting the content of ester oil, component (D), in relation to the content of TRPM8 agonist, component (B), as described above, is advantageous in that the skin irritation of TRPM8 agonist is suppressed, the duration of the cooling sensation is improved, and the adsorption of TRPM8 agonist to the pillow is suppressed. From this viewpoint, it is preferable to set the mass ratio of component (B) / component (D) in the gel layer to 0.05 or higher, more preferably to 0.06 or higher, and even more preferably to 0.07 or higher. From a similar viewpoint, it is preferable to set the mass ratio of component (B) / component (D) in the gel layer to 0.5 or less, more preferably to 0.45 or less, even more preferably to 0.4 or less, and even more preferably to 0.3 or less. Considering the above points, it is preferable that the mass ratio of component (B) / component (D) be 0.05 or more and 0.5 or less, more preferably 0.06 or more and 0.45 or less, even more preferably 0.07 or more and 0.4 or less, and even more preferably 0.07 or more and 0.3 or less.

[0026] If component (B) contains the above-mentioned components (B1) and (B2), it is preferable to set the mass ratio of component (B1) / component (D) to 0.01 or more and 0.5 or less, particularly 0.025 or more and 0.45 or less, and especially 0.05 or more and 0.4 or less, from the viewpoint of further enhancing the blood circulation promoting effect, alleviating the stimulating sensation of the TRPM8 agonist, and allowing the user to fully perceive the effect of a clear head. From a similar viewpoint, it is preferable that the mass ratio of component (B2) / component (D) be 0.05 or more and 0.5 or less, particularly 0.06 or more and 0.45 or less, and especially 0.07 or more and 0.4 or less.

[0027] In addition to the components mentioned above, the gel layer may also contain other components commonly used in cosmetics and pharmaceuticals. Examples of such components include powder components, humectants, water-soluble polymers, thickeners, film-forming agents, UV absorbers, metal ion sequestering agents, alcohols, sugars, amino acid derivatives, organic amines, synthetic resin emulsions, known blood circulation promoters, skin nutrients, vitamins, antioxidants, antioxidant aids, preservatives, pigments, and fragrances.

[0028] The gel layer contains a gelling agent. The gelling agent retains water, which is component (C), thereby obtaining a gel layer consisting of a hydrogel. Preferably, the gelling agent contains a water-soluble anionic polymer. It is also preferable that the gelling agent contains a crosslinking agent for the water-soluble anionic polymer. The water-soluble anionic polymer and its crosslinking agent form a dense network structure that forms the basic framework of the gel layer, and water is retained within this network structure.

[0029] Examples of water-soluble anionic polymers include polymers having carboxyl groups, sulfate groups, and phosphate groups. Specifically, these include poly(meth)acrylic acids, carboxyvinyl polymers and their salts; anionic cellulose derivatives such as carboxymethylcellulose and carboxyethylcellulose and their salts; carrageenan, alginic acid and their salts, and anionic starch derivatives. From the viewpoint of high water retention, sufficient gel strength, and flexibility that can follow the contours of the skin and body movements, it is preferable that the water-soluble anionic polymer contains at least one selected from poly(meth)acrylic acids, carboxymethylcellulose, carrageenan, and their salts. Furthermore, it is even more preferable to use carboxymethylcellulose, sodium carboxymethylcellulose, polyacrylic acid, and sodium polyacrylate because they are relatively inexpensive and readily available industrially.

[0030] The anionic polymer content in the gel layer is preferably 0.5% by mass or more and 25% by mass or less, in order to impart sufficient gel strength to the gel layer. From this viewpoint, the anionic polymer content in the gel layer is more preferably 3% by mass or more and 10% by mass or less.

[0031] Examples of crosslinking agents for water-soluble anionic polymers include metal ion compounds, cationic polymers, and polyfunctional epoxy compounds. The choice of crosslinking agent should depend on the reactivity between the functional groups of the anionic polymer to be crosslinked and the crosslinking agent.

[0032] Examples of the aforementioned metal ion compounds include oxides, hydroxides, and salts containing aluminum, magnesium, calcium, or potassium. Specifically, examples include aluminum hydroxide, potassium alum, aluminum sulfate, aluminum oxide, aluminum glycinate, aluminum acetate, aluminum lactate, aluminum stearate, hydrated aluminum silicate, aluminum metasilicate, magnesium aluminometasilicate, magnesium chloride, magnesium stearate, calcium carbonate, calcium hydroxide, kaolin, synthetic hydrotalcite, and potassium hydroxide. These compounds may be used individually or in combination of two or more. When carboxymethylcellulose or its salts are selected as the anionic polymer, it is preferable to use aluminum ion compounds such as magnesium aluminometasilicate and aluminum hydroxide as crosslinking agents. From the viewpoint of sufficiently crosslinking the anionic polymer, the content of the crosslinking agent in the gel layer is preferably 0.01% by mass or more and 10% by mass or less, more preferably 0.05% by mass or more and 5% by mass or less, and even more preferably 0.1% by mass or more and 2% by mass or less.

[0033] The body-adhesive sheet of the present invention may have a gel layer supported on one surface of a sheet substrate. Examples of sheet substrates include woven fabrics, nonwoven fabrics, knitted fabrics, synthetic resin films, and water-resistant paper. Laminate sheets consisting of a combination of two or more of these materials can also be used. Specific examples of sheet substrates include woven or nonwoven fabrics containing synthetic fibers such as polyamide, polypropylene, polyester, polyethylene, polystyrene, polyurethane, or polyolefin, or natural fibers such as silk, cotton, linen, rayon, or collagen. In addition, synthetic resin sheets made of polyamide, polypropylene, polyester, polyethylene, and polyurethane, as well as thin film sheets made of pullulan and starch, can also be used. From the standpoint of ensuring sufficient strength for use, the sheet substrate may have a thickness of approximately 0.05 mm to 2.0 mm under no load.

[0034] The body-adhesive sheet of the present invention may have a release layer laminated on the surface of the gel layer. If the body-adhesive sheet of the present invention has, for example, a sheet substrate and a gel layer disposed on one side thereof, the release layer can be disposed on the side of the gel layer opposite to the side facing the sheet substrate. The release layer is used for the purpose of protecting the gel layer in the body-adhesive sheet before use. When using the body-adhesive sheet, the release layer is peeled off from the gel layer to expose one side of the gel layer, and the sheet is attached to the human body by using the adhesive properties of the gel layer to bring that side into contact with the human body.

[0035] Examples of substrates for the release layer include polyester films such as polyethylene terephthalate film and polybutylene terephthalate film; polyolefin films such as polyethylene film and polypropylene film; and laminated paper in which a synthetic resin film such as polyethylene is laminated onto paper such as kraft paper, glassine paper, or fine paper. It is more preferable that one side of the release layer is hydrophobized, such as by silicone treatment. In this case, the release layer is laminated with the gel layer such that the hydrophobized side faces the gel layer.

[0036] The body-adhesive sheet of the present invention is preferably contained airtightly in a packaging container before use, in order to maintain the concentration of carbon dioxide gas contained in the gel layer. From this viewpoint, the packaging container is preferably made of a material that is poorly permeable to carbon dioxide gas. For example, a carbon dioxide gas permeability of 50 cc / m³ 2 It is preferable that the packaging container is made of a material with a day·atm (ASTM D-1434) or less.

[0037] To incorporate carbon dioxide into the gel layer, a body-adhesive sheet can be placed inside a packaging container, and the packaging container can be sealed while it is filled with carbon dioxide. A specific method is described, for example, in Japanese Patent Publication No. 2021-31105, an earlier application of the present applicant.

[0038] The body-adhesive sheet of the present invention is used by being applied to human skin other than the scalp. Specific application sites include, for example, various parts of the face such as the forehead, cheeks, nose, ears, and mouth, as well as the upper body of a person, such as the neck (especially the nape), shoulders, back, waist, chest, upper arms, and forearms. Applying it to the forehead, neck (especially the nape), or shoulders is particularly preferable as it enhances the effects of the present invention. However, there is no prejudice to applying the body-adhesive sheet of the present invention to the lower limbs of a person, such as the calves, thighs, ankles, and soles of the feet. Notably, even when the body adhesive sheet of the present invention is not applied to the forehead but to other parts of the body, it is possible to make the user perceive the effect of a clearer head. Moreover, even when the body adhesive sheet of the present invention is applied to other parts of the body other than the forehead, such as the neck or shoulders, it is possible to make the user perceive the effect of a clearer head without perceiving an excessively strong sensation. Of course, even when the body adhesive sheet of the present invention is applied to the forehead, it is possible to make the user perceive the effect of a clearer head. Thus, the body adhesive sheet of the present invention is particularly useful as a sheet for cooling the human head. In this specification, "cooling the human head" is a concept that encompasses not only physically cooling the head by applying the body adhesive sheet of the present invention to the human head (for example, by cooling through the heat of vaporization of water), but also applying the body adhesive sheet of the present invention to a part of the body other than the head to make the user perceive the effect of having a refreshed head. Therefore, "head cooling sheet" refers to a sheet that is applied to the human body and used to cool the head.

[0039] As mentioned earlier, the body adhesive sheet of the present invention contains a large amount of carbon dioxide in the gel layer, resulting in a higher blood circulation promoting effect compared to conventional water-containing gel sheets. Therefore, even if the sheet is made smaller, it is possible to make the user feel a pleasant cooling sensation and a sense of mental clarity. From this perspective, the area of ​​the gel layer in the body adhesive sheet of the present invention is 40 cm². 2 Preferably, it should be 45 cm or more. 2 It is even more preferable that it be greater than or equal to 50 cm. 2 It is even more preferable that the above conditions are met. Furthermore, the area of ​​the gel layer in the body adhesive sheet of the present invention is 90 cm². 2 Preferably, it is 85cm 2 It is even more preferable that the following be the case: 80cm 2 The following is even more preferable. The area mentioned above refers to the area of ​​the gel layer in a plan view, even when the body-adhesive sheet of the present invention has a sheet substrate and / or a release layer in addition to the gel layer.

[0040] In relation to the area described above, when the gel layer in the body-adhesive sheet of the present invention is rectangular, the length of one side is preferably 3 cm or more, more preferably 3.5 cm or more, and even more preferably 4 cm or more. Furthermore, the length of one side is preferably 30 cm or less, more preferably 25 cm or less, and even more preferably 22.5 cm or less. Furthermore, the shape of the gel layer in the body-adhesive sheet of the present invention, when viewed from above, is not limited to a rectangle, but may be other shapes, such as a circle, an ellipse, or a polygon other than a rectangle. Also, if the body-adhesive sheet of the present invention has a sheet substrate and / or a release layer in addition to the gel layer, the shape of the gel layer and the shape of the sheet substrate and / or release layer may be the same or different.

[0041] With regard to the embodiments described above, the present invention further discloses the following body-adhesive sheets. <1> A body adhesive sheet having a gel layer, The gel layer comprises the following components (A), (B), and (C): (A) Carbon dioxide (B) TRPM8 Agonist (C)Water It contains, The content of component (A) in the gel layer is 5 g / m 2 That's all. The content of component (B) in the gel layer is 0.001% by mass or more and 0.20% by mass or less. A body-adhesive sheet having a gel layer thickness of 1.5 mm or more. <2> The content of component (B) in the gel layer is 0.01% by mass or more and 0.20% by mass or less. <1> Body adhesive sheets as described. <3> The content of component (B) in the gel layer is 0.05% by mass or more and 0.15% by mass or less. <1> or <2> Body adhesive sheets as described. <4> Component (B) is composed of component (B1) and component (B2): (B1) Menthoxypropanediol or Menthyl Lactate (B2) Menthol Contains <1> or <3> A body-adhesive sheet described in any one of the following. <5> The content of component (B1) in the gel layer is 0.001% by mass or more and 0.191% by mass or less. <4> Body adhesive sheets as described. <6> The content of component (B1) in the gel layer is 0.0015% by mass or more and 0.165% by mass or less. <4> or <5> Body adhesive sheets as described. <7> The content of component (B1) in the gel layer is 0.002% by mass or more and 0.143% by mass or less. <4> or <6> A body-adhesive sheet described in any one of the following. <8> The content of component (B2) in the gel layer is 0.0005% by mass or more and 0.182% by mass or less. <4> or <7> A body-adhesive sheet described in any one of the following. <9> The content of component (B2) in the gel layer is 0.005% by mass or more and 0.159% by mass or less. <4> or <8> A body-adhesive sheet described in any one of the following. <10> The content of component (B2) in the gel layer is 0.0075% by mass or more and 0.136% by mass or less. <4> or <9> A body-adhesive sheet described in any one of the following. <11> The mass ratio of component (B2) / component (B1) is between 0.05 and 10. <4> or <10> A body-adhesive sheet described in any one of the following. <12> The mass ratio of component (B2) / component (B1) is between 0.1 and 9. <4> or <11> A body-adhesive sheet described in any one of the following. <13> The mass ratio of component (B2) / component (B1) is between 0.25 and 8. <4> or <12> A body-adhesive sheet described in any one of the following. <14> The mass ratio of component (B2) / component (B1) is between 0.8 and 4. <4> or <13> A body-adhesive sheet described in any one of the following. <15> The component (B1) is menthoxypropanediol. The component (B2) is menthol. <4> or <14> A body-adhesive sheet described in any one of the following. <16> The aforementioned gel layer further comprises the following component (D): (D) Ester oil It contains, The mass ratio of component (B) / component (D) is 0.05 or more and 0.5 or less. <1> or <15> A body-adhesive sheet described in any one of the following. <17> The mass ratio of component (B) / component (D) is 0.06 or more and 0.45 or less. <16> Body adhesive sheets as described. <18> The mass ratio of component (B) / component (D) is 0.07 or more and 0.4 or less. <16> or <17> Body adhesive sheets as described. <19> The content of component (D) in the gel layer is 0.01% by mass or more and 3% by mass or less. <16> or <18> A body-adhesive sheet described in any one of the following. <20> The content of component (D) in the gel layer is 0.05% by mass or more and 2.8% by mass or less. <16> or <19> A body-adhesive sheet described in any one of the following. <21> The content of component (D) in the gel layer is 0.1% by mass or more and 2.5% by mass or less. <16> or <20> A body-adhesive sheet described in any one of the following. <22> Component (B) is composed of component (B1) and component (B2): (B1) Menthoxypropanediol or Menthyl Lactate (B2) Menthol The aforementioned gel layer further comprises the following component (D): (D) Ester oil It contains, The mass ratio of component (B1) / component (D) is 0.01 or more and 0.5 or less. <1> or <3> A body-adhesive sheet described in any one of the following. <23> The mass ratio of component (B1) / component (D) is between 0.025 and 0.45. <22> Body adhesive sheets as described. <24> The mass ratio of component (B1) / component (D) is 0.05 or more and 0.4 or less. <22> or <23> Body adhesive sheets as described. <25> Component (B) is composed of component (B1) and component (B2): (B1) Menthoxypropanediol or Menthyl Lactate (B2) Menthol The aforementioned gel layer further comprises the following component (D): (D) Ester oil It contains, The mass ratio of component (B2) / component (D) is 0.05 or more and 0.5 or less. <1> or <3> A body-adhesive sheet described in any one of the following. <26> The mass ratio of component (B2) / component (D) is 0.06 or more and 0.45 or less. <25> Body adhesive sheets as described. <27> The mass ratio of component (B2) / component (D) is 0.07 or more and 0.4 or less. <26> or <26> Body adhesive sheets as described. <28> The content of component (A) in the gel layer is 5 g / m 2 More than 80g / m 2 The following is: <1> or <27> A body-adhesive sheet described in any one of the following.

[0042] <29> The content of component (A) in the gel layer is 5.5 g / m². 2 More than 60g / m 2 The following is: <1> or <28> A body-adhesive sheet described in any one of the following. <30> The content of component (A) in the gel layer is 6 g / m². 2 More than 40g / m 2 The following is: <1> or <29> A body-adhesive sheet described in any one of the following. <31> The content of component (A) in the gel layer is 6 g / m². 2 More than 20g / m 2 The following is: <1> or <30> A body-adhesive sheet described in any one of the following. <32> The concentration of component (A) in the gel layer is 750 ppm or more. <1> or <31> A body-adhesive sheet described in any one of the following. <33> The concentration of component (A) in the gel layer is 1000 ppm or more. <1> or <32> A body-adhesive sheet described in any one of the following. <34> The concentration of component (A) in the gel layer is 1250 ppm or more. <1> or <33> A body-adhesive sheet described in any one of the following. <35> The content of component (C) in the gel layer is 60% by mass or more and 90% by mass or less. <1> or <34> A body-adhesive sheet described in any one of the following. <36> The content of component (C) in the gel layer is 65% by mass or more and 87% by mass or less. <1> or <35> A body-adhesive sheet described in any one of the following. <37> The content of component (C) in the gel layer is 70% by mass or more and 85% by mass or less. <1> or <36> A body-adhesive sheet described in any one of the following. <38> The gel layer contains a gelling agent. <1> or <37> A body-adhesive sheet described in any one of the following. <39> The gelling agent comprises a water-soluble anionic polymer. <38> Body adhesive sheets as described. <40> The content of the water-soluble anionic polymer in the gel layer is 0.5% by mass or more and 25% by mass or less. <39> Body adhesive sheets as described. <41> The gelling agent includes a crosslinking agent for the water-soluble anionic polymer. <39> or <40> Body adhesive sheets as described. <42> The content of the crosslinking agent in the gel layer is 0.01% by mass or more and 10% by mass or less. <41> Body adhesive sheets as described. <43> The basis weight of the gel layer is 1500 g / m². 2 That's all. <1> or <42> A body-adhesive sheet described in any one of the following. <44> The basis weight of the gel layer is 1500 g / m². 2 More than 3200g / m 2 The following is: <1> or <43> A body-adhesive sheet described in any one of the following. <45> The basis weight of the gel layer is 1700 g / m². 2 More than 3200g / m 2 The following is: <1> or <44> A body-adhesive sheet described in any one of the following. <46> The basis weight of the gel layer is 1900 g / m². 2 More than 3200g / m 2 The following is: <1> or <45> A body-adhesive sheet described in any one of the following. <47> The thickness of the gel layer is 1.5 mm or more and 10 mm or less. <1> or <46> A body-adhesive sheet described in any one of the following. <48> The thickness of the gel layer is 2 mm or more and 8 mm or less. <1> or <47> A body-adhesive sheet described in any one of the following. <49> The thickness of the gel layer is 3 mm or more and 6 mm or less. <1> or <48> A body-adhesive sheet described in any one of the following. <50> Area 40cm 2 More than 90cm 2 The following is: <1> or <49> A body-adhesive sheet described in any one of the following. <51> The gel layer is supported on one surface of the sheet substrate. <1> or <50> A body-adhesive sheet described in any one of the following. <52> The sheet substrate is a woven fabric, nonwoven fabric, knitted fabric, synthetic resin film, or water-resistant paper. <1> or <51> A body-adhesive sheet described in any one of the following. <53> In its pre-use state, it is airtightly contained within the packaging container. <1> or <52> A body-adhesive sheet described in any one of the following. <54> Carbon dioxide permeability is 50 cc / m³ 2 The packaging container is made of materials that are below day·atm (ASTM D-1434). <53> Body adhesive sheets as described. <55> It is applied to the human body and used to cool the head. <1> or <54> A body-adhesive sheet described in any one of the following. [Examples]

[0043] The present invention will be described in more detail below with reference to examples. However, the scope of the present invention is not limited to these examples. Unless otherwise specified, "%" means "mass%".

[0044] [Examples 1 to 18 and Comparative Examples 1 to 6] A hydrated gel stock solution in an uncrosslinked state was prepared according to the formulations shown in Tables 1 to 3 below, and a patch for body application was made using this hydrated gel stock solution. Specifically, a succinic acid aqueous solution was mixed with sodium carboxymethylcellulose, polyvinyl alcohol, dried aluminum hydroxide, magnesium aluminometasilicate, glycerin, glutamic acid, and methyl parahydroxybenzoate, and then put into a kneader. Next, propylene glycol in which TRPM8 agonist (component (B)) had been heated and dissolved was added and mixed to prepare an uncrosslinked hydrated gel stock solution. The obtained hydrated gel stock solution was sandwiched between a polyethylene film and a nonwoven fabric, and the thickness of the gel layer was adjusted using a Baker-type applicator. Then, the gel was aged at 50°C for 2 days to promote the ionic crosslinking reaction of the hydrated gel. In the table, "WS-5," one of the components (B), is the trade name for N-(ethoxycarbonylmethyl)-3-p-menthanecarboxamide, a TRPM8 agonist manufactured by Renessenz LLC. The body-adhesive sheets obtained in this manner were die-cut into 5cm x 10cm rectangles and placed inside pillow packaging made of synthetic resin film coated with aluminum. The air inside the packaging was replaced with carbon dioxide by 90% or more by volume before sealing. The carbon dioxide content and concentration in the gel layer of the examples and comparative examples were changed by adjusting the thickness and / or basis weight and / or water content of the gel layer.

[0045] The body-adhesive sheets obtained in this manner were removed from their packaging, and the thickness of the gel layer, basis weight, and carbon dioxide content and concentration in the gel layer were promptly measured. Furthermore, the body-adhesive sheets removed from the packaging were promptly applied to the forehead and back of the neck of the subjects. After 180 minutes, the degree of skin irritation, the duration of the cooling sensation, and the perceived effect of refreshing the head were evaluated according to the following criteria, and the rate of increase in blood flow was measured. The subjects were three healthy adult men and women. The results are shown in Tables 1 to 3 below.

[0046] [Low skin irritation] ○: It is comfortable to use without causing any irritation. △: Slightly irritating. ×: Causes strong irritation (cannot keep applied).

[0047] [Longevity of cooling sensation] ◎: Provides a long-lasting cooling sensation. ○: Provides a long-lasting cooling sensation. △: The cooling sensation lasts for a short time. ×: The cooling sensation doesn't last very long.

[0048] [I felt the effect of clearing my head.] ◎: I feel a noticeable sense of mental clarity. ○: I feel a sense of mental clarity. △: I feel a slight sense of mental clarity. ×: I don't feel mentally clear.

[0049] [Percentage increase in blood flow] After acclimatizing subjects for 20 minutes in an environment of approximately 25±1°C and 50±5%RH, blood flow in the medial forearm was measured using a laser speckle blood flowmeter and recorded as the pre-measurement value. Blood flow was measured 5 minutes, 30 minutes, 60 minutes, and 120 minutes after each gel sheet was applied to the medial forearm. The percentage increase in blood flow after application was calculated, with the pre-application blood flow being set to 100.

[0050] [Table 1]

[0051] [Table 2]

[0052] [Table 3]

[0053] As is clear from the results shown in Tables 1 to 3, the body adhesive sheets of each example, when applied to the user's skin, can provide a sufficient and continuous cooling sensation without causing excessive irritation, and also provide a refreshing effect on the head. This effect is particularly pronounced when two compounds are used in combination as TRPM8 agonists. In particular, as is clear from the comparison between Example 1 and Example 16, when menthoxypropanediol and menthol are used as TRPM8 agonists in combination (Example 1), a sufficient and continuous cooling sensation can be provided without causing excessive irritation to the user, and a refreshing effect on the head can be felt, compared to when other combinations are used (Example 16). Furthermore, while conventional methods increased blood flow by using high concentrations of TRPM8 agonists, as shown in each example, it can be seen that even when using low concentrations of TRPM8 agonists, increasing the amount of carbon dioxide per unit area increases the amount of blood flow increase. In contrast, in Comparative Example 1, which had a higher TRPM8 agonist content, users experienced strong irritation, and their comfort level was diminished. This trend can also be observed in Comparative Example 3, which had a higher carbon dioxide content than Comparative Example 1. In Comparative Example 2, which did not contain the TRPM8 agonist, users did not experience strong irritation, but they also did not feel a noticeable effect of clearing their heads. In Comparative Example 4, which had a low carbon dioxide content, users did not experience strong stimulation due to the low TRPM8 agonist content. However, because the blood circulation-promoting effect of carbon dioxide was low, users were unable to experience a refreshing effect on their heads.

Claims

1. A body adhesive sheet having a gel layer, The gel layer comprises the following components (A), (B), and (C): (A) Carbon dioxide (B) TRPM8 agonist (C) Water It contains, The content of component (A) in the gel layer is 5 g / m ２ That's all. The content of component (B) in the gel layer is 0.001% by mass or more and 0.20% by mass or less. A body-adhesive sheet having a gel layer thickness of 1.5 mm or more.

2. Component (B) is composed of component (B1) and component (B2): (B1) Menthoxypropanediol or Menthyl Lactate (B2) Menthol A body-adhesive sheet according to claim 1, comprising the same material.

3. The body adhesive sheet according to claim 2, wherein the mass ratio of component (B2) / component (B1) is 0.05 or more and 10 or less.

4. The aforementioned gel layer further comprises the following component (D): (D) Ester oil It contains, The body adhesive sheet according to claim 1 or 2, wherein the mass ratio of component (B) / component (D) is 0.05 or more and 0.5 or less.

5. The body-adhesive sheet according to claim 1 or 2, wherein the concentration of component (A) in the gel layer is 750 ppm or more.

6. The body adhesive sheet according to claim 1 or 2, wherein the content of component (C) in the gel layer is 60% by mass or more and 90% by mass or less.

7. The basis weight of the gel layer is 1500 g / m². ２ The body-adhesive sheet according to claim 1 or 2.

8. Area 40 cm ２ More than 90cm ２ The body-adhesive sheet according to claim 1 or 2, which is as follows:

9. A body-adhesive sheet according to claim 1 or 2, which is applied to the human body and used to cool the head.

Images